“Mistakes that resulted in clinical data that was much more complex to interpret than Moderna’s and Pfizer’s. And on top of that the efficacy is lower.” Technology, price and storage. The AstraZeneca ...

It will compare the ... According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

COVID products are still a profit driver for the company. Pfizer is forecast by Wall Street to report $5.3 billion in 2024 ...

Vaccines, however, which have prevented 6 million deaths every year worldwide and have fundamentally changed modern medicine, should not be on that list. The benefit of vaccines is not a matter of ...

joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. Both Moderna and Pfizer made history during the COVID-19 pandemic thanks to mRNA ...

Background: The safety and immunogenicity of Viatim, a combined hepatitis A (HA) and typhoid fever (Vi) vaccine, were compared with the monovalent component vaccines up to and 1 month after a ...

Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. HealthDay News — The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

If you could save lives by producing vaccines in transgenic bananas, would you? In the debate over large-scale commercialization and use of GMOs, where should we draw the line? Vaccines Tobacco ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...